"The highest doses of orforglipron caused people to lose an average of 27 pounds after 72 weeks of treatment, showcasing its effectiveness as a weight loss solution."
"Foundayo is the second GLP-1 weight-loss pill to gain FDA approval, following Novo Nordisk's Wegovy, which was approved in December 2025."
"Experts hope that having more options for these popular weight-loss and type 2 diabetes treatments will drive down costs and offer people more flexibility."
"Generally it's much easier to make pills and distribute them, compared with injectable drugs, which should help in reaching a wider population."
Eli Lilly's orforglipron, a once-daily weight loss pill, received FDA approval, marking the fastest approval of a new medication in decades. Clinical trials indicated that the highest doses led to an average weight loss of 27 pounds after 72 weeks. This medication is the second GLP-1 weight-loss pill approved, following Novo Nordisk's Wegovy. Experts believe that more options will reduce costs and improve accessibility. The ease of distribution for pills compared to injectables is expected to widen the drug's reach.
Read at www.scientificamerican.com
Unable to calculate read time
Collection
[
|
...
]